Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Biosimilars
Real-World Data Showed Comparable pCR Rates with Neoadjuvant Chemotherapy plus Trastuzumab-dkst versus Trastuzumab
Read More
Biosimilars
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for the Treatment of High-Risk, HER2-Positive Early Breast Cancer
Read More
Biosimilars
Real-World Overall Response Rate and Other Outcomes Related to Originator and Biosimilar Rituximab in Patients with CLL or NHL in the United Kingdom
Read More
Meeting Highlights
Biosimilars
,
ASCO Highlights
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Chase Doyle
Chase Doyle
Read More
Biosimilars
Biosimilars Year in Review Introduction
Read More
Biosimilars
Establishing Analytical and Clinical Similarity Between HD201 and Trastuzumab
Read More
Biosimilars
Population-Based, Real-World Data of Neoadjuvant Chemotherapy + Pertuzumab + SB3 in HER2-Positive, Early Breast Cancer
Read More
Biosimilars
Cost-Savings from Conversion from Reference Pegfilgrastim with On-Body Injector Device to Biosimilar Pegfilgrastim-jmdb in DLBCL
Read More
Biosimilars
Pharmacokinetic and Safety Equivalence Demonstrated Between HD204, a Biosimilar of Bevacizumab, in Healthy Male Subjects
Read More
Biosimilars
Utilization and Adherence Among Infliximab Biosimilar Initiators in a US National Commercial Insurance Database
Read More
1
2
3
4
5
6
7
Page 4 of 7
Results 31 - 40 of 65